tiprankstipranks
Trending News
More News >
Celcuity (CELC)
NASDAQ:CELC
US Market
Advertisement

Celcuity (CELC) Earnings Dates, Call Summary & Reports

Compare
456 Followers

Earnings Data

Report Date
Mar 19, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-1.05
Last Year’s EPS
-0.85
Same Quarter Last Year
Based on 9 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflects a strong position for Celcuity, with significant clinical and regulatory progress, a solid financial foundation, and promising market potential. However, the increased financial loss and regulatory uncertainties present challenges that need to be addressed.
Company Guidance
During the Celcuity Third Quarter 2025 Financial Results Webcast, the company provided guidance on several key metrics. They highlighted significant clinical and regulatory milestones, including top-line data results from the PIK3CA wild-type cohort of the Phase III VICTORIA-one study and detailed efficacy and safety results presented at the European Society for Medical Oncology (ESMO) Congress. The median progression-free survival (PFS) for the triplet therapy was 9.3 months, with a hazard ratio of 0.24, while the doublet therapy showed a median PFS of 7.4 months with a hazard ratio of 0.33. Additionally, Celcuity completed a concurrent offering resulting in net proceeds of $287 million and increased their term loan facility to $500 million. The company also discussed their strategic plans for the potential launch of Get It Solicit, citing a total addressable market in the U.S. for the second-line setting estimated at $5 billion to $6 billion, and potential peak revenues of $2.5 billion to $3 billion. They expect cash and investments to fund operations through 2027.
Progress in Clinical and Regulatory Milestones
Significant achievements in clinical trials, including presenting positive data from the PIK3CA wild-type cohort of the VICTORIA-one trial, and FDA's acceptance of the NDA under the real-time oncology review program.
Strong Financial Position
Completion of concurrent offerings resulting in net proceeds of approximately $287 million and an increase in the term loan facility to $500 million, providing substantial financial flexibility.
Positive Clinical Trial Results
In the VICTORIA-one trial, the triplet therapy showed a 7.3-month incremental improvement in median PFS, with hazard ratios more favorable than previously reported.
Solid Market Potential
With a total addressable market estimated at $5 billion to $6 billion, potential peak revenues for Get It Solicit are projected at $2.5 billion to $3 billion.
Progress in Commercial Launch Preparations
Significant progress in building the organization and systems required for a potential launch, alongside positive feedback from key opinion leaders and decision-makers.

Celcuity (CELC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CELC Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 19, 2026
2025 (Q4)
-1.05 / -
-0.85
Nov 12, 2025
2025 (Q3)
-1.02 / -0.92
-0.7-31.43% (-0.22)
Aug 14, 2025
2025 (Q2)
-0.88 / -1.04
-0.62-67.74% (-0.42)
May 14, 2025
2025 (Q1)
- / -0.86
-0.64-34.37% (-0.22)
Mar 31, 2025
2024 (Q4)
-0.86 / -0.86
-0.64-34.37% (-0.22)
Nov 14, 2024
2024 (Q3)
-0.65 / -0.70
-0.8315.66% (+0.13)
Aug 14, 2024
2024 (Q2)
-0.68 / -0.62
-0.666.06% (+0.04)
May 15, 2024
2024 (Q1)
-0.70 / -0.64
-0.55-16.36% (-0.09)
Mar 27, 2024
2023 (Q4)
-0.73 / -0.65
-0.695.80% (+0.04)
Nov 13, 2023
2023 (Q3)
-0.68 / -0.83
-0.63-31.75% (-0.20)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CELC Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
$85.15$86.00+1.00%
Aug 14, 2025
$51.89$51.79-0.19%
May 14, 2025
$10.86$10.52-3.13%
Mar 31, 2025
$10.11$9.29-8.11%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Celcuity (CELC) report earnings?
Celcuity (CELC) is schdueled to report earning on Mar 19, 2026, After Close (Confirmed).
    What is Celcuity (CELC) earnings time?
    Celcuity (CELC) earnings time is at Mar 19, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CELC EPS forecast?
          CELC EPS forecast for the fiscal quarter 2025 (Q4) is -1.05.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis